Targets › CSFL1R
1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on CSFL1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Wei Zhao | PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor G-CSF receptor agonist | CSFL1R | Phase 4 | Hematological Neoplasms | Dec 2026 |
Hematological Neoplasms (1)
mixed (1)
Wei Zhao (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.